These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 13680159

  • 1. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
    Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ.
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):449-52. PubMed ID: 13680159
    [Abstract] [Full Text] [Related]

  • 2. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
    Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F.
    Cancer; 2003 Mar 15; 97(6):1481-7. PubMed ID: 12627513
    [Abstract] [Full Text] [Related]

  • 3. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
    Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ.
    Leuk Res; 2003 Oct 15; 27(10):893-7. PubMed ID: 12860008
    [Abstract] [Full Text] [Related]

  • 4. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
    Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ.
    Cancer Chemother Pharmacol; 2003 Jan 15; 51(1):87-90. PubMed ID: 12497211
    [Abstract] [Full Text] [Related]

  • 5. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
    Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ.
    Cancer Chemother Pharmacol; 2002 Dec 15; 50(6):497-500. PubMed ID: 12451477
    [Abstract] [Full Text] [Related]

  • 6. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, Piccaluga PP, Michelutti A, Simeone E, Damiani D, Russo D, Fanin R.
    Leuk Res; 2008 Dec 15; 32(12):1800-8. PubMed ID: 18621416
    [Abstract] [Full Text] [Related]

  • 7. [Current and new therapeutic strategies in acute myeloid leukemia].
    Naito K, Ohnishi K.
    Gan To Kagaku Ryoho; 2005 Mar 15; 32(3):292-6. PubMed ID: 15791811
    [Abstract] [Full Text] [Related]

  • 8. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH.
    J Clin Oncol; 1997 Aug 15; 15(8):2780-5. PubMed ID: 9256119
    [Abstract] [Full Text] [Related]

  • 9. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Aug 15; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 10. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
    Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M.
    Leuk Res; 2004 Apr 15; 28(4):353-7. PubMed ID: 15109534
    [Abstract] [Full Text] [Related]

  • 11. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.
    Br J Haematol; 2005 Oct 15; 131(2):172-9. PubMed ID: 16197446
    [Abstract] [Full Text] [Related]

  • 12. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H.
    Clin Lymphoma Myeloma Leuk; 2012 Aug 15; 12(4):244-51. PubMed ID: 22534616
    [Abstract] [Full Text] [Related]

  • 13. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
    Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW.
    Blood; 2003 Dec 15; 102(13):4277-83. PubMed ID: 12933575
    [Abstract] [Full Text] [Related]

  • 14. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M.
    Haematologica; 1996 Dec 15; 81(6):513-20. PubMed ID: 9009438
    [Abstract] [Full Text] [Related]

  • 15. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 16. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 15; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 17. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
    Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, Pastori G, Guardo D, Colombo N, Kunkl A, Fugazza G, Rebesco B, Sessarego M, Lemoli RM, Bacigalupo A, Gobbi M.
    Am J Hematol; 2016 Aug 15; 91(8):755-62. PubMed ID: 27084986
    [Abstract] [Full Text] [Related]

  • 18. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar 15; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 19. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
    Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ.
    Leuk Lymphoma; 1993 Mar 15; 9(4-5):343-50. PubMed ID: 8394169
    [Abstract] [Full Text] [Related]

  • 20. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.
    Ann Hematol; 2008 May 15; 87(5):361-7. PubMed ID: 18074133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.